{"componentChunkName":"component---node-modules-gatsby-theme-buzzing-src-gatsby-theme-blog-core-templates-post-query-js","path":"/ja/reddit/r/investing/comments/lku7ah/hey_all_here_is_some_dd_on_txmd/","result":{"data":{"site":{"siteMetadata":{"title":"国外股市热门","author":"Buzzing.cc","description":"用中文浏览国外股票社区里的热门讨论","keywords":["buzzing","美股","股票","股市"],"siteUrl":"https://stocks.buzzing.cc","telegram":"@stocks_top","iconUrl":"https://stocks.buzzing.cc/avatar.png","defaultSocialImageUrl":null,"social":[{"name":"Reddit Stocks","url":"https://www.reddit.com/r/stocks","external":true},{"name":"Reddit Investing","url":"https://www.reddit.com/r/investing","external":true},{"name":"Charlie Bilello's twitter","url":"https://twitter.com/charliebilello","external":true},{"name":"Buzzing","url":"https://www.buzzing.cc/","external":true}],"menuLinks":[{"name":"每周精选","url":"/issues","external":null}],"disqus":null,"utterances":null,"localize":[{"title":"Buzzing on Stocks","description":"See popular discussions in foreign stock communities in your native language","keywords":["buzzing","stocks","U.S. stocks"],"locale":"en","social":{"name":null,"url":null,"external":null},"menuLinks":[{"name":"Weekly Selection","url":"/en/issues","external":null}]},{"title":"國外股市熱門","description":"用中文瀏覽國外股票社區裡的熱門討論","keywords":["buzzing","美股","股票","股市"],"locale":"zh-Hant","social":null,"menuLinks":[{"name":"每週精選","url":"/zh-Hant/issues","external":null}]},{"title":"米国株式市場人気の話し合います","description":"人気の米国株式市場の話し合いまを日本語で閲覧","keywords":["buzzing","米国株式市場"],"locale":"ja","social":null,"menuLinks":[]}]}},"blogPost":{"id":"RedditPost-33ebabfb-93c3-5071-a7fe-e497f25502de","excerpt":"I AM NOT A FINANCIAL ADVISOR\n\n$TXMD - TherapeuticsMD, Inc. is an innovative, leading healthcare company,\nfocused on developing and commercializing novel products exclusively for women.\nTheir products are designed to address the unique changes and challenges women\nexperience through the various…","body":"<!-- SC_OFF --><div class=\"md\"><p>I AM NOT A FINANCIAL ADVISOR</p>\n\n<p><strong>$TXMD</strong> - TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Their products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues.</p>\n\n<p>- On Feb. 11 they announced the pricing of its underwritten public offering of approximately 59.5 million shares of its common stock for gross proceeds of $110 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by TXMD. The offering is expected to close on February 16 (tomorrow). In addition, TXMD has granted the underwriter a 30-day option to purchase up to approximately 8.9 million additional shares of common stock.</p>\n\n<p>- Drug pipeline below:</p>\n\n<ol>\n<li>TXMD announces the submission of a New Drug Application for TX-001HR (Bijuva- a pill for the treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause) in December.</li>\n<li>Bijuva - The first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women.</li>\n<li>Segesterone Acetate - The first and only patient-controlled, procedure-free, long-acting, reversible prescription birth control product to provide a full year of protection from pregnancy.</li>\n<li>Yuvvexy - an applicator-free, vaginal, estradiol softgel capsule being proposed for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.</li>\n</ol>\n\n<p>- Market Watch rates this stock as a buy, with a high stock price at $10, a median of $7, and a low of $3. It&#39;s current price is $1.92</p>\n</div><!-- SC_ON -->","slug":"/reddit/r/investing/comments/lku7ah/hey_all_here_is_some_dd_on_txmd/","title":"Hey all, here is some DD on $TXMD","tags":["investing","reddit"],"date":"February 16, 2021","dateISO":"2021-02-16T13:41:24.000Z","datetime":"2021-02-16 13:41","image":null,"imageAlt":null,"socialImage":null,"__typename":"SocialMediaPost","thirdPartyId":"33ebabfb-93c3-5071-a7fe-e497f25502de","provider":"Reddit","url":"https://www.reddit.com/r/investing/comments/lku7ah/hey_all_here_is_some_dd_on_txmd/","originalUrl":"https://www.reddit.com/r/investing/comments/lku7ah/hey_all_here_is_some_dd_on_txmd/","imageRemote":null,"video":null,"channel":"investing","channelUrl":"https://www.reddit.com/r/investing","author":"PDWAMMO","authorUrl":"https://www.reddit.com/user/PDWAMMO","authorImage":null,"authorImageRemote":null,"authorSlug":"PDWAMMO","score":78,"views":null,"sharedCount":null,"likeCount":null,"sharedContent":null,"parent":{"localize":[{"title":"大家好，这里是$TXMD的一些DD。","the_new_excerpt":"我不是财务顾问\n\n$TXMD - TherapeuticsMD公司是一家创新的、领先的医疗保健公司。\n专注于开发和商业化女性专用的新型产品。\n他们的产品旨在解决女性的独特变化和挑战。\n经验，通过各种...","locale":"zh"},{"title":"大家好，這裏是$TXMD的一些DD。","the_new_excerpt":"我不是財務顧問\n\n$TXMD - TherapeuticsMD公司是一家創新的、領先的醫療保健公司。\n專注於開發和商業化女性專用的新型產品。\n他們的產品旨在解決女性的獨特變化和挑戰。\n經驗，通過各種...","locale":"zh-Hant"}]}},"previous":{"id":"RedditPost-1433cc24-fc7b-5e0b-bbb5-d9da23da689a","excerpt":"EDIT: COULDN'T EDIT THE TITLE; THE LOSS PER SHARE TOTALED $0.08 VERSUS THE\nPOSITIVE $0.02 CONSENSUS.\n\nPalantir Technologies Q4 GAAP EPS of -$0.08 misses by $0.1.\n\nRevenue of $322.09M (+40.4% Y/Y) beats by $21.02M.\n\nIn Q4 2020, the company signed 21 contracts each worth $5M or more in total\ncontract…","slug":"/reddit/r/stocks/comments/ll2ih4/palantir_technologies_eps_beats_by_006_beats_on/","title":"Palantir Technologies EPS beats by $0.06, beats on revenue, expects Q1 revenue growth of 45%","date":"February 16, 2021","__typename":"SocialMediaPost","parent":{"localize":[{"title":"Palantir科技EPS胜过0.06元，胜过营收，预计Q1营收增长45%。","the_new_excerpt":"编辑：无法编辑标题；每股亏损总计0.08美元，而不是。\n正向0.02美元咨询。\n\nPalantir Technologies Q4 GAAP EPS为-0.08美元，差0.1美元。\n\n营收3.2209亿元(+40.4%Y/Y)胜过2102万元。\n\n2020年第四季度，公司签署了21份合同，每份合同总价值在500万美元以上\n合同...","locale":"zh"},{"title":"Palantir科技EPS勝過0.06元，勝過營收，預計Q1營收增長45%。","the_new_excerpt":"編輯：無法編輯標題；每股虧損總計0.08美元，而不是。\n正向0.02美元諮詢。\n\nPalantir Technologies Q4 GAAP EPS爲-0.08美元，差0.1美元。\n\n營收3.2209億元(+40.4%Y/Y)勝過2102萬元。\n\n2020年第四季度，公司簽署了21份合同，每份合同總價值在500萬美元以上\n合同...","locale":"zh-Hant"}]}},"next":{"id":"RedditPost-6d96a7bc-ee60-5ea1-958e-8208d339cfa3","excerpt":"My perfect exit strategy? Hold. Tell people I have a small position. Tell my\nfamily I only bought a couple shares as I like to be diverse and hold 45 stocks\nin my portfolio (LOL). Tell my friends (greedy blood suckers) that I FOMO'd in\nat $33 instead of going all-in at $9.00. Lock up my shares.…","slug":"/reddit/r/wallstreetbets/comments/lkwazx/dwight_schrute_owns_palantir/","title":"Dwight Schrute owns Palantir","__typename":"SocialMediaPost","date":"February 16, 2021","parent":{"localize":[{"title":"德怀特-施鲁特拥有Palantir公司","the_new_excerpt":"我的完美退出策略？持有。告诉别人我有一个小仓位。告诉我的...\n家庭我只买了几只股票，因为我喜欢多样化，持有45只股票。\n在我的作品集里（LOL）。告诉我的朋友（贪婪的吸血者），我FOMO'd在\n在33美元，而不是在9.00美元的时候全仓。锁定我的股票....","locale":"zh"},{"title":"德懷特-施魯特擁有Palantir公司","the_new_excerpt":"我的完美退出策略？持有。告訴別人我有一個小倉位。告訴我的...\n家庭我只買了幾隻股票，因爲我喜歡多樣化，持有45只股票。\n在我的作品集裏（LOL）。告訴我的朋友（貪婪的吸血者），我FOMO'd在\n在33美元，而不是在9.00美元的時候全倉。鎖定我的股票....","locale":"zh-Hant"}]}}},"pageContext":{"basePath":"/","pageType":"detail","id":"RedditPost-33ebabfb-93c3-5071-a7fe-e497f25502de","previousId":"RedditPost-1433cc24-fc7b-5e0b-bbb5-d9da23da689a","nextId":"RedditPost-6d96a7bc-ee60-5ea1-958e-8208d339cfa3","maxWidth":1024,"siteMetadata":null,"locale":"ja","hrefLang":"ja-JA","originalPath":"/reddit/r/investing/comments/lku7ah/hey_all_here_is_some_dd_on_txmd/","dateFormat":"YYYY-MM-DD"}},"staticQueryHashes":["1239077767","2744905544","3280999885"]}